Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Unresolved deficiencies at a third party manufacturing facility are what tripped Astellas up in its bid for approval of zolbetuximab, according to the companys announcement of the Jan
P.GomesB
With insurance coverage, a savings card, or a manufacturer direct program, the actual cost can be $25 to $449 per month
Favorable laboratory findings were consistent with those observed in the Phase III rheumatoid arthritis study and other early clinical studies with no adverse impact in hemoglobin, neutrophils, or lymphocytes or elevations in ALT or AST
US$ 28.78
US$ 28.25
US$ 27.96
US$ 24.29
US$ 22.36
US$ 29.32
US$ 21.41
US$ 28.27
US$ 21.44
